KVISTGAARD, Denmark, February 9, 2012 - Bavarian Nordic (NASDAQ OMX: BAVA) announced today that it will present at the 14th Annual BIO CEO & Investor Conference in New York on Tuesday, February 14, 2012 at 2:00 p.m. ET.
The presentation will be held by Rolf Sass Sørensen, Vice President Investor Relations and Communications.
About Bavarian Nordic
Bavarian Nordic is a vaccine-focused biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline targets cancer and infectious diseases, and includes ten development programs. In oncology, the company's lead program is PROSTVAC®, a therapeutic vaccine candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial and is being developed under a collaboration agreement with the National Cancer Institute. In infectious diseases, the company's lead program is IMVAMUNE®, a third-generation smallpox vaccine candidate that is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government.
For more information, visit www.bavarian-nordic.com.
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Bavarian Nordic A/S via Thomson Reuters ONE
HUG#1584214